CompletedNCT04860830
Iclepertin for learning and memory in schizophrenia: CONNEX-3
About this title
Read the official source — NCT04860830Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Medication studyAges 18–50Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Anaheim and 109 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: August 9, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 609
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, United Kingdom, Belgium, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT04860830
- Official title
Show the full official title
A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-3)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Anaheim, United States · Culver City, United States · Los Angeles, United States
96 more locations
- Pico Rivera, United States
- Stanford, United States
- Walnut Creek, United States
- Hollywood, United States
- Maitland, United States
- Miami, United States
- Orlando, United States
- Atlanta, United States
- Augusta, United States
- Gaithersburg, United States
- St Louis, United States
- Omaha, United States
- Berlin, United States
- Raleigh, United States
- Dayton, United States
- Oklahoma City, United States
- State College, United States
- Houston, United States
- Richmond, United States
- Banfield, Argentina
- CABA, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Rosario, Argentina
- San Vicente, Argentina
- Vienna, Austria
- Bertix, Belgium
- Bierbeek, Belgium
- Duffel, Belgium
- Mechelen, Belgium
- Rio de Janeiro, Brazil
- São Paulo, Brazil
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Beijing, China
- Changsha, China
- Guangzhou, China
- Huzhou, China
- Nanjing, China
- Shenzhen, China
- Shijiazhuang, China
- Tianjin, China
- Xi'an, China
- Zhumadian, China
- Klecany, Czechia
- Ostrava, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Říčany, Czechia
- Aalborg, Denmark
- Aarhus, Denmark
- Glostrup Municipality, Denmark
- Espoo, Finland
- Helsinki, Finland
- Turku, Finland
- Böblingen, Germany
- Dortmund, Germany
- Mainz, Germany
- München, Germany
- Tübingen, Germany
- Kaunas, Lithuania
- Šilutė, Lithuania
- Vilnius, Lithuania
- Chihuahua City, Mexico
- Culiacán, Mexico
- León, Mexico
- Mexico City, Mexico
- Monterrey, Mexico
- San Luis Potosí City, Mexico
- Leiria, Portugal
- Lisbon, Portugal
- Loures, Portugal
- Belgrade, Serbia
- Gornja Toponica, Serbia
- Busan, South Korea
- Daegu, South Korea
- Gwangju, South Korea
- Seongnam, South Korea
- Seongnam-si, South Korea
- Yangsan, South Korea
- Kaohsiung City, Taiwan
- Keelung, Taiwan
- Taichung, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
- Taoyuan County, Taiwan
- Bodmin, United Kingdom
- Cheltenham, United Kingdom
- Chester, United Kingdom
- Edinburgh, United Kingdom
- Glasgow, United Kingdom
- London, United Kingdom
- Oxford, United Kingdom
- Southampton, United Kingdom
- Czechia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including Iclepertin and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia